Clinical Trials Logo

Clinical Trial Summary

The investigators hypothesize that in patients with shift work sleep disorder, armodafinil will specifically increase brain activity in the frontal cortex parallel with improvements in deficits of fundamental mechanisms of attention.


Clinical Trial Description

The current protocol will utilize a paradigm which is well suited to examine frontal attentional neuronal mechanisms by eliciting event related potential components known to reflect automatic stimulus detection as well as involuntary and voluntary attentional processes. The that end the proposed research has two specific aims. 1) Identify what areas of the frontal lobe and corresponding cognitive functions are impacted by excessive sleepiness in shift work sleep disorder and 2) identify specific brain areas affected by armodafinil and their role in improvement of fundamental attentional processes using a complex cognitive task targeting attentional control. ;


Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT00688142
Study type Observational
Source Henry Ford Health System
Contact
Status Completed
Phase N/A
Start date February 2008
Completion date March 2010

See also
  Status Clinical Trial Phase
Completed NCT00080288 - Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD Phase 3
Terminated NCT01792583 - The Nuvigil and Provigil Pregnancy Registry